Overview - The company, Xilong Science Co., Ltd., has announced the provision of guarantees for financing credit applications by its subsidiaries for the year 2025, with a total guarantee amount not exceeding RMB 3.75 billion [2][3]. Guarantee Details - The total guarantee amount provided by the company for its subsidiaries is capped at RMB 2.085 billion, with specific allocations based on the subsidiaries' asset-liability ratios: up to RMB 1.635 billion for those with a ratio of 70% or less, and up to RMB 450 million for those exceeding 70% [2]. - Subsidiaries can also provide guarantees for each other, with a total amount not exceeding RMB 55 million, allocated similarly based on asset-liability ratios [2]. - The company can provide guarantees for its own financing credit applications, with a total amount not exceeding RMB 1.61 billion [2]. Guarantee Agreements - The company has signed a maximum guarantee contract with Bank of China, Chengdu branch, providing a joint liability guarantee for its subsidiary, Sichuan Xilong Science Co., Ltd., with a maximum principal amount of RMB 55 million [4][6]. - A guarantee contract has also been signed with Shanghai Rural Commercial Bank, providing a guarantee for Shanghai Xilong Chemical Co., Ltd., with a principal amount of RMB 10 million [4][6]. Guarantee Period and Conditions - The guarantee period for the contracts is set from June 17, 2025, to June 16, 2026, with a guarantee duration of three years following the debt fulfillment deadline [7][8]. - The guarantees cover not only the principal but also interest, penalties, and other related costs incurred due to defaults [6][7]. Current Guarantee Status - As of the announcement date, the company and its subsidiaries have a total of zero external guarantees, excluding those provided for the consolidated subsidiaries [8]. - The actual guarantee balances for the controlling subsidiaries are RMB 849.08 million, and the guarantees provided by subsidiaries to each other total RMB 1 million, representing 36.92%, 33.58%, and 0.43% of the company's latest audited net assets, respectively [8].

证券代码：002584 证券简称：西陇科学 公告编号：2025-031 西陇科学股份有限公司 关于对合并报表范围内子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 一、 担保情况概述 西陇科学股份有限公司（以下简称"西陇科学"或"公司"）第六届董事会第八次 会议审议通过了《关于公司及子公司对 2025 年度融资授信提供担保的议案》。 2025 年度，根据公司及子（孙）公司的生产经营和资金需求情况，公司及子（孙） 公司为合并报表范围内公司向金融机构申请融资授信提供担保，担保额度总计不 超过人民币 37.5 亿元。具体如下： 公司为纳入合并报表范围的子（孙）公司向金融机构申请融资授信提供担保， 总额不超过人民币20.85亿元，其中对最近一期资产负债率小于等于70%的子（孙） 公司担保额度不超过人民币 16.35 亿元，对最近一期资产负债率超 70%的子（孙） 公司担保额度不超过人民币 4.5 亿元；子（孙）公司为合并范围内其他子（孙） 公司向金融机构申请融资授信提供担保，总额不超过人民币 0.55 亿元，其中对最 近一期资产负债率小于等于 ...

Core Viewpoint - The in vitro diagnostics sector experienced a slight increase of 0.24% on July 4, with a net outflow of funds amounting to 42.33 million [1] Group 1: Market Performance - A total of 18 stocks in the sector saw gains, while 49 stocks declined [1] - The top decliners included Dongfang Ocean (-6.51%), Xilong Scientific (-3.81%), and Nearshore Protein (-2.54%) [1][1] Group 2: Stock Performance - Notable gainers included: - Hotgen Biotech with a price of 194.81 and an increase of 20.08%, attracting a net fund inflow of 2.125 million [1] - Saily Medical at 21.08, up 10.02%, with a net inflow of 1.758 million [1] - Zhongyuan Union at 25.87, rising 9.99%, with a net inflow of 1.38 billion [1] - Decliners included: - Botao Biotech at 37.34, down 3.38%, with a net outflow of 1.087 million [1] - Maike Biotech at 7.99, down 2.44%, with a net inflow of 176.92 thousand [1]

西陇科学股份有限公司 关于对合并报表范围内子公司提供担保的进展公告 证券代码：002584 证券简称：西陇科学 公告编号：2025-030 禅城支行《授信协议》下发生的债务提供最高额保证担保，所担保债权的最高 本金余额为人民币肆仟贰佰伍拾万元整。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 一、 担保情况概述 西陇科学股份有限公司（以下简称"西陇科学"或"公司"）第六届董事会第八次 会议审议通过了《关于公司及子公司对 2025 年度融资授信提供担保的议案》。 2025 年度，根据公司及子（孙）公司的生产经营和资金需求情况，公司及子（孙） 公司为合并报表范围内公司向金融机构申请融资授信提供担保，担保额度总计不 超过人民币 37.5 亿元。具体如下： 公司为纳入合并报表范围的子（孙）公司向金融机构申请融资授信提供担保， 总额不超过人民币20.85亿元，其中对最近一期资产负债率小于等于70%的子（孙） 公司担保额度不超过人民币 16.35 亿元，对最近一期资产负债率超 70%的子（孙） 公司担保额度不超过人民币 4.5 亿元；子（孙）公司为合并范围内其他子（孙） ...

Group 1 - The recombinant protein sector experienced a decline of 1.53%, ranking among the top declines in concept sectors as of the market close on May 26 [1][2] - Within the recombinant protein sector, notable declines were observed in companies such as Sanofi (三生国健) and Yipin Pharmaceutical (一品红), while a few companies like ST Wanfang (*ST万方) and Xilong Science (西陇科学) saw increases of 3.19% and 2.76% respectively [1][2] Group 2 - The recombinant protein sector faced a net outflow of 276 million yuan, with 33 stocks experiencing net outflows, and 17 stocks seeing outflows exceeding 10 million yuan [2] - The stock with the highest net outflow was Sanofi (三生国健), which had a net outflow of approximately 46.36 million yuan, followed by companies like Betta Pharmaceuticals (贝达药业) and Xilong Science (西陇科学) with net outflows of 32.77 million yuan and 29.11 million yuan respectively [2][3] Group 3 - The top gainers in the recombinant protein sector included ST Wanfang (*ST万方) and Kaiyin Technology (凯因科技), which saw net inflows of 9.82 million yuan and 11.86 million yuan respectively [3] - Other companies with significant net inflows included Guoyao Modern (国药现代) with 14.46 million yuan and Rejing Biological (热景生物) with 35.44 million yuan [3]

Group 1 - The recombinant protein concept sector rose by 2.52%, ranking second among concept sectors, with 30 stocks increasing in value [1][2] - Notable gainers included Sangon Biotech, which hit the daily limit with a 20% increase, and other significant performers such as Sai Sheng Pharmaceutical, Jie Ya Co., and Jinbo Bio, which rose by 16.37%, 9.31%, and 9.17% respectively [1][2] - The sector experienced a net inflow of 221 million yuan from main funds, with 23 stocks receiving net inflows, and 8 stocks exceeding 10 million yuan in net inflow [2][3] Group 2 - Leading the net inflow was Xilong Scientific, which saw a net inflow of 242 million yuan, followed by Rejuve Pharmaceutical and Zexin Pharmaceutical with net inflows of 37.78 million yuan and 32.48 million yuan respectively [2][3] - The top three stocks by net inflow ratio were Xilong Scientific at 20.85%, Zexin Pharmaceutical at 8.53%, and Chengdu Xian Dao at 7.96% [3][4] - Stocks with notable declines included Furuida, Zhongyuan Xiehe, and Wanmei Biological, which fell by 2.25%, 1.92%, and 1.80% respectively [1][5]

西陇科学股份有限公司（以下简称"西陇科学"或"公司"）第六届董事会第八次 会议审议通过了《关于公司及子公司对 2025 年度融资授信提供担保的议案》。 2025 年度，根据公司及子（孙）公司的生产经营和资金需求情况，公司及子（孙） 公司为合并报表范围内公司向金融机构申请融资授信提供担保，担保额度总计不 超过人民币 37.5 亿元。具体如下： 证券代码：002584 证券简称：西陇科学 公告编号：2025-029 西陇科学股份有限公司 关于合并报表范围内公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 一、 担保情况概述 公司为纳入合并报表范围的子（孙）公司向金融机构申请融资授信提供担保， 总额不超过人民币20.85亿元，其中对最近一期资产负债率小于等于70%的子（孙） 公司担保额度不超过人民币 16.35 亿元，对最近一期资产负债率超 70%的子（孙） 公司担保额度不超过人民币 4.5 亿元；子（孙）公司为合并范围内其他子（孙） 公司向金融机构申请融资授信提供担保，总额不超过人民币 0.55 亿元，其中对最 近一期资产负债率小于等于70% ...

证券代码：002584 证券简称：西陇科学 公告编号：2025-028 西陇科学股份有限公司 2024 年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重要提示： 1、本次股东大会无否决提案的情形。 2、本次股东大会无变更以往股东大会已通过决议的情形。 一、会议召开的情况 1、会议召开时间： （1）现场会议召开时间：2025 年 5 月 16 日 14:30 开始。 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为： 2025 年 5 月 16 日 9:15—9:25,9:30—11:30 和 13:00—15:00；通过深圳证券交易所 互联网投票系统进行投票的时间为：2025 年 5 月 16 日上午 9:15 至 15:00。 2、会议召开地点：广州市黄埔区新瑞路 6 号公司 5 楼会议室。 3、会议召开方式：现场投票与网络投票结合的方式召开。 6、本次股东大会的召集、召开与表决程序符合《公司法》、《深圳证券交易所 股票上市规则》、《上市公司股东大会规则》及《公司章程》等法律、法规及规范 性文件的规定。 二、会议的出 ...

北京中银律师事务所 关于西陇科学股份有限公司 2024 年度股东大会的 法律意见书 地址：北京市朝阳区光华路正大中心北塔 11-12 层 网址：www.zhongyinlawyer.com 电话：65876666 法律意见书 北京中银律师事务所 关于西陇科学股份有限公司 2024 年度股东大会的法律意见书 致：西陇科学股份有限公司 北京中银律师事务所（以下称"本所"）接受西陇科学股份有限公司（以下简 称"公司"）的委托，根据《中华人民共和国公司法》等法律、行政法规、规范性 文件及《西陇科学股份有限公司章程》（以下简称"《公司章程》"）的有关规定， 就公司 2024 年度股东大会（以下简称"本次股东大会"）的召集、召开程序、出席 人员及召集人资格、大会表决程序、表决结果等事宜，出具法律意见。 本所及经办律师依据《中华人民共和国证券法》《律师事务所从事证券法律业 务管理办法》和《律师事务所证券法律业务执业规则》等规定及本法律意见出具日 以前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实信用 原则，进行了充分的核查验证，保证本法律意见书所认定的事实真实、准确、完整， 所发表的结论性意见合法、准确， ...

Financial Performance - The company achieved a net profit attributable to shareholders of 61.77 million yuan in 2024, representing an increase of 85.24% compared to the previous year [2] Dividend Distribution - In 2024, the company conducted two cash dividend distributions: 1. In July 2024, a cash dividend of 0.2 yuan per 10 shares was distributed, totaling 11,704,328.44 yuan (including tax) [3] 2. In December 2024, a cash dividend of 0.33 yuan per 10 shares was proposed, totaling 19,312,141.93 yuan (including tax) [3] Business Performance - The gross margin for the specialized chemical business dropped to 1% due to high volatility in silver prices, which constitute a significant portion of product costs [4] - The company is actively participating in the photovoltaic industry to expand market share, even with low margins, to establish a competitive advantage [4] Future Outlook - The performance compensation expected to be paid in 2025 may impact the company's consolidated financial results, with the final amount to be determined through negotiations with relevant parties [4]